Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, doubleblind, randomized, placebocontrolled Trial with Abciximab to reduce coronary microembolism during PCI in patient with stable angina pectoris.

Next Previous
Trial Profile

Prospective, doubleblind, randomized, placebocontrolled Trial with Abciximab to reduce coronary microembolism during PCI in patient with stable angina pectoris.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abciximab (Primary)
  • Indications Embolism
  • Focus Biomarker; Therapeutic Use
  • Acronyms REOPRO-HITS

Most Recent Events

  • 09 Feb 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2010-019688-12).
  • 09 Feb 2013 Planned End Date (18 Apr 2011) added as reported by European Clinical Trials Database.
  • 06 Jul 2012 Planned initiation date (12 Dec 2010) added as reported by German Clinical Trials Register record..

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top